SEC Form 6-K filed by Grifols S.A.

$GRFS
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $GRFS alert in real time by email
6-K 1 tm2428869d1_6k.htm FORM 6-K

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of November 2024

 

Commission File No. 001-35193

 

Grifols, S.A.

(Translation of registrant’s name into English)

 

Avinguda de la Generalitat, 152-158

Parc de Negocis Can Sant Joan

Sant Cugat del Valles 08174

Barcelona, Spain

(Address of registrant’s principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F x                                             Form 40-F ¨

 

 

 

 

 

 

Grifols, S.A.

 

TABLE OF CONTENTS

 

Item   Sequential Page Number
     
1. Inside Information Note, dated November 19, 2024 3

 

 

 

 

 

 

Grifols, S.A.
 
Avinguda de la Generalitat 152-158
08174 Sant Cugat del Vallès
Barcelona - ESPAÑA
 
Tel. [34] 935 710 500
Fax [34] 935 710 267
 
www.grifols.com

 

Pursuant to the provisions of article 226 of the Consolidated Text of the Securities Market Act, approved by the Legislative Royal Decree 4/2015, of 23 October, Grifols, S.A. ("Grifols") hereby informs about the following

 

INSIDE INFORMATION

 

In relation to the inside information note sent today to the CNMV by Brookfield Capital Partners (UK) Limited, Grifols announces that its Board of Directors will hold an extraordinary meeting this afternoon to analyse the information received. Subsequently, it will issue an opinion regarding Brookfield's communication. The directors who are in conflict of interest will not participate in the issuance of such opinion.

 

Grifols also announces that the Transaction Committee of the Board of Directors has duly considered Brookfield’s non-binding indicative valuation of €6.45Bn for the entire outstanding share capital of the Company (the aggregate of Class A and B shares), implying an indicative price of €10.50 per share for Class A shares, and has concluded that a potential offer at this valuation level significantly undervalues the Company’s fundamental prospects and its long-term potential. Accordingly, the Transaction Committee would not be in a position to recommend to the Board of Directors to support an offer at this valuation for the Company nor to recommend to the shareholders of the Company the acceptance of a potential offer at the indicated price. The Transaction Committee communicated this fact to Brookfield and has requested the call for the extraordinary meeting referred to above.

 

In Barcelona, on 19 November 2024.

 

  

Thomas Glanzmann

Chairman of the Board of Directors

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.

 

  Grifols, S.A.
     
  By: /s/ David I. Bell
    Name: David I. Bell
    Title: Authorized Signatory

 

Date:  November 19, 2024

 

 

 

Get the next $GRFS alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$GRFS

DatePrice TargetRatingAnalyst
2/12/2025Overweight
Morgan Stanley
3/12/2024Hold → Sell
Deutsche Bank
4/12/2023Equal-Weight → Overweight
Morgan Stanley
3/3/2023Overweight → Equal-Weight
Morgan Stanley
2/16/2023Underweight → Equal Weight
Barclays
1/18/2023Hold → Buy
Jefferies
4/8/2022Equal-Weight
Morgan Stanley
11/5/2021Buy → Hold
Deutsche Bank
More analyst ratings

$GRFS
Press Releases

Fastest customizable press release news feed in the world

See more
  • Grifols Pioneers High-Tech Analysis of Plasma Bank to Detect Early Signs of Parkinson's Disease

    ‘Chronos-PD' is looking for biological signals that could indicate increased chance of developing Parkinson's disease (PD) years before symptoms appear, leading to new diagnostic tools and disease-modifying therapiesPart of broad Grifols program to find disease-revealing clues in more than 100 million proprietary plasma samples connected to real-world data on thousands of disease states in many therapeutic areasCutting-edge use of AI and proteomics technology paired with real-world evidence underscores the company's ongoing commitment to bold scientific innovation to benefit patients BARCELONA, Spain, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Grifols ((MCE: GRF, MCE: GRF.P, NASDAQ:GRFS), a global

    $GRFS
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Mason Capital Management Sends Letter to Spanish National Securities Market Commission Regarding Lack of Transparency by Grifols

    Urges Improved Disclosure Around Key Issues for the Benefit of Grifols Shareholders Mason Capital Management LLC ("Mason"), a registered investment advisor to funds and accounts holding approximately 2.5% of Grifols S.A. ("Grifols" or the "Company") (BME: GRF) (NASDAQ:GRFS) class A shares, today sent a letter to the Spanish National Securities Market Commission (the "CNMV") calling the CNMV's attention to the troubling and value destructive lack of transparency by Grifols and its Board of Directors (the "Board"). In the letter, Mason urges the CNMV to consider the benefits to all Grifols shareholders from improved disclosure around several key issues, including: Related-party transac

    $GRFS
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Mason Capital Management Requests Immediate Disclosure of Important Information Regarding Conflicted Grifols Director Tomas Daga

    Urges Board to Prove its Independence by Accepting Tomas Daga's Voluntary Resignation Mason Capital Management LLC ("Mason"), a registered investment advisor to funds and accounts holding approximately 2.1% of Grifols S.A. ("Grifols" or the "Company") (BME: GRF) (NASDAQ:GRFS) class A shares, today sent a letter to the Grifols Board of Directors (the "Board") requesting the disclosure of important information regarding Tomas Daga, a nearly 25-year member of the Board and the Grifols family's closest advisor, so that Grifols shareholders have a better understanding of his relationship to Grifols and can make an informed decision about the suitability of his continued service on the Board.

    $GRFS
    Biotechnology: Pharmaceutical Preparations
    Health Care

$GRFS
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$GRFS
SEC Filings

See more

$GRFS
Leadership Updates

Live Leadership Updates

See more
  • Mason Capital Management Highlights Corporate Governance Failures and Significant Shareholder Value Destruction Under Grifols Board of Directors

    Sends Letter to Board Detailing Board's Conflicts of Interest and History of Poor Capital Allocation Expresses Urgent Need for Independent Directors and Proper Oversight to Unlock Value Believes Rumored Brookfield Transaction Substantially Undervalues Grifols Mason Capital Management LLC ("Mason"), a registered investment advisor to funds and accounts holding approximately 2.1% of Grifols S.A. ("Grifols" or the "Company") (BME: GRF) (NASDAQ:GRFS) class A shares, today sent a letter to the Grifols Board of Directors (the "Board"). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241107873955/en/Historical Forward EV/EBITDA Multip

    $GRFS
    $SYN
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Grifols 2022 Annual Report on Form 20-F filed with the SEC on April 18, 2023

    BARCELONA, Spain, April 18, 2023 /PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE: GRF) (MCE: GRF.P) (NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines that has been enhancing people's health and well-being for more than 110 years, today announces the filling of its Annual Report on Form 20-F for the fiscal year ended December 31, 2022, with the United States Securities and Exchange Commission ("SEC"). Grifols' annual report under Form 20-F is a critical component of the company's commitment to transparency and accountability. The filing of the annual report provides investors with an overview of the company's governance practices, including informa

    $GRF
    $GRFS
    Finance/Investors Services
    Finance
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Victor Grifols Roura decides to retire as Chairperson; Grifols appoints private equity veteran Steven F. Mayer as Executive Chairperson

    Victor Grifols Roura, who devoted 50 years to building Grifols in senior roles including CEO for 30 years, retires as non-executive Chairperson and is designated as Chairperson of Honor in recognition of his numerous contributionsSteven F. Mayer, former Co-Head of Global Private Equity and Chairman of the Investment Committee of private investment firm Cerberus Capital Management, L.P., with more than 10 years serving as a Grifols independent board member, is appointed as Executive ChairpersonChanges further evidence of the Board of Directors' focus on strategic objectives, operational excellence, and deleveraging balance sheetBARCELONA, Spain, Oct. 3, 2022 /PRNewswire/ -- Grifols (MCE: GRF)

    $GRFS
    Biotechnology: Pharmaceutical Preparations
    Health Care

$GRFS
Financials

Live finance-specific insights

See more
  • Grifols acquires its first plasma donation center in Canada

    BARCELONA, Spain, Jan. 4, 2022 /PRNewswire/ -- Grifols ((MCE: GRF, MCE: GRF.P, NASDAQ:GRFS), a global healthcare company and one of world's top producers of plasma-derived medicines, today announced the acquisition of its first donation center in Canada as part of the company's commitment to increase the availability of lifesaving plasma medicines in the country. In a share-purchase agreement, Grifols Canada Therapeutics Inc has acquired Prometic Plasma Resources Inc's (PPR) donation center in Winnipeg from Kedrion for USD 4 million in cash. With the center, Grifols furthers

    $GRFS
    Biotechnology: Pharmaceutical Preparations
    Health Care

$GRFS
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more